# US 2010/0166791 A1 · Circovirus sequences associated with piglet weight loss disease (pwd)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166791 A1
- Document ID: US20100166791A1
- Status: Published application
- Kind: A1
- Application number: 12/561,829
- Filed: 2009-09-17
- Published: 2010-07-01
- Earliest claimed: 1997-12-05
- Assignees: Wyeth
- Inventors: André Jestin; Emmanuel Albina; Pierre Le Cann; Philippe Blanchard; Evelyne Hutet; Claire Arnauld; Catherine Truong; Dominique Mahe; Roland Cariolet; François Madec
- Web page: https://patentgrep.com/patent/US20100166791A1

## CPC

- A61K 39/12: Viral antigens
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 33/00: Antiparasitic agents
- A61P 37/02: Immunomodulators
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- G01N 33/56983: {Viruses}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/525: {Virus}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C12N 2710/14143: viral genome or elements thereof as genetic vector
- C12N 2750/10021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2750/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2750/10051: Methods of production or purification of viral material
- C12N 2750/10061: Methods of inactivation or attenuation
- G01N 2333/01: DNA viruses
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- Y10T 428/13: Hollow or container type article [e.g., tube, vase, etc.]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

## Claims

### Claim 1

A vaccine for the prevention or treatment of a viral infection by a piglet weight loss disease circovirus.

### Claim 2

A vaccine for the prevention or treatment of a viral infection by a piglet weight loss disease circovirus, wherein said vaccine comprises a nucleotide sequence from the genome of porcine circovirus type B, or a homolog or fragment thereof.

### Claim 3 (depends on 2)

The vaccine of claim 2, wherein said nucleotide sequence is selected from SEQ ID NO. 15, SEQ ID NO. 19, SEQ ID NO. 23, and SEQ ID NO. 25.

### Claim 4 (depends on 2)

The vaccine of claim 2, wherein said homolog has at least 80% sequence identity to SEQ ID NO. 15, SEQ ID NO. 19, SEQ ID NO. 23, or SEQ ID NO. 25.

### Claim 5

A vaccine comprising a polypeptide encoded by a nucleotide sequence from the genome of porcine circovirus type B.

### Claim 6 (depends on 5)

The vaccine of claim 5, further comprising a pharmaceutical or veterinary vehicle.

### Claim 7 (depends on 5)

The vaccine of claim 5, wherein said polypeptide has the amino acid sequence selected from SEQ ID NO. 24 and SEQ ID NO. 26.

### Claim 8

A method of immunizing an animal against piglet weight loss disease, comprising administering to an animal an effective amount of a vaccine, wherein said vaccine comprises a nucleotide sequence from the genome of porcine circovirus type B.

### Claim 9

A method of immunizing an animal against piglet weight loss disease, comprising administering to an animal an effective amount of a vaccine, wherein said vaccine comprises a polypeptide encoded by a nucleotide sequence from the genome of porcine circovirus type B.

### Claim 10

An immunogenic agent comprising a polypeptide selected from SEQ ID NO. 29, SEQ ID NO. 30, SEQ ID NO. 31, and SEQ ID NO. 32.

### Claim 11 (depends on 10)

A medicament comprising the immunogenic agent of claim 10.

### Claim 12 (depends on 1)

The vaccine of claim 1, comprising at least one antigen of a porcine circovirus type B.
